Chemistry:Envudeucitinib
From HandWiki
Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for the treatment of autoimmune diseases. Envudeucitinib targets the TYK2 signaling pathway, which plays a crucial role in regulating multiple pro-inflammatory cytokines such as IL-12, IL-23, and type I interferons.[1][2]
References
- ā "Recent progress on tyrosine kinase 2 JH2 inhibitors". International Immunopharmacology 121. August 2023. doi:10.1016/j.intimp.2023.110434. PMID 37315371.
- ā "Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway". Journal of Cutaneous Medicine and Surgery 27 (1_suppl): 3Sā24S. 2023. doi:10.1177/12034754221141680. PMID 36519621.
 |  |
